Regulus Therapeutics
RGLS
RGLS was delisted on the 24th of June, 2025.
31 hedge funds and large institutions have $24.8M invested in Regulus Therapeutics in 2020 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 8 increasing their positions, 3 reducing their positions, and 7 closing their positions.
518% more capital invested
Capital invested by funds: $4.02M → $24.8M (+$20.8M)
171% more call options, than puts
Call options by funds: $92K | Put options by funds: $34K
167% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 3
57% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 7
15% more funds holding
Funds holding: 27 → 31 (+4)
0.72% more ownership
Funds ownership: 2.18% → 2.9% (+0.72%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$3.23M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$2.36M |
| 3 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$1.18M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$367K |
| 5 |
Renaissance Technologies
New York
|
+$330K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$56K |
| 2 |
WS
Wedbush Securities
Los Angeles,
California
|
-$36K |
| 3 |
Millennium Management
New York
|
-$25K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
-$21.6K |
| 5 |
BlackRock
New York
|
-$11K |
RGLS Hedge Fund Activity: Q4 2020 in Review
31 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Regulus Therapeutics (RGLS) for Q4 2020, worth a combined $24.8M — up 518% from $4.02M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new RGLS positions and 7 closed out — a net gain of 4 holders — while 8 added to existing stakes and 3 trimmed.
The largest buyer was NEA Management Company, adding an estimated $3.23M. The largest seller was Citadel Advisors, exiting entirely with an estimated $56K sold.
- 31 institutional investors held Regulus Therapeutics (RGLS) as of Q4 2020, up from 27 in Q3 2020.
- Funds reported $24.8M of Regulus Therapeutics stock for Q4 2020, up 518% quarter-over-quarter.
- 11 funds opened new Regulus Therapeutics positions in Q4 2020 and 7 closed out, a net change of +4 holders.
- The largest Regulus Therapeutics buyer in Q4 2020 was NEA Management Company, an estimated $3.23M added.
- The largest Regulus Therapeutics seller in Q4 2020 was Citadel Advisors, an estimated $56K sold.
Based on aggregated 13F filings for Q4 2020.